“Based on our strong performance in the quarter, we are pleased to raise our full year sales guidance by $2 billion and EPS guidance by $0.25 a from $10.60 to $10.85.”

In context

“care company operating in both the med tech and innovative medicine sectors. In the second quarter, we delivered operational sales growth of 4.6% across our business. In Innovative Medicines, we reported 3.8% operational sales growth, delivering more than $15 billion in quarterly sales for the first time. No other health care company has grown through the loss of exclusivity of a multibillion dollar product in the first year. In our case, STELARA and yet that is exactly what we are doing. And for the second quarter in a row. Our performance was driven by double-digit growth across 3 brands including DARZALEX, CARVYKTI, [indiscernible] as well as [indiscernible] and in medtech, we delivered 6.1% operational sales growth with particularly strong momentum in cardiovascular surgery ambition. Based on our strong performance in the quarter, we are pleased to raise our full year sales guidance by $2 billion and EPS guidance by $0.25 a from $10.60 to $10.85. Results like this are a direct result of our deep and resilient portfolio. It's what makes Johnson & Johnson unique. Today, we will focus on the remarkable ways we are driving innovation and creating value for patients and shareholders. We will highlight the depth of our portfolio and pipeline focusing on 6 areas of unmet need and where we are delivering significant growth. Oncology, immunology, neuroscience, cardiovascular, surgery ambition. These are spaces where we are moving the conversation from treatment to cure and where we are extending and improving lives in meaningful ways. Let's start with innovative medicine and oncology, where we have a bold vision to eliminate cancer. Our leading products for the treatment of blood cancers and solid tumors are built on cutting-edge scientifi”